Session

Prostate cancer: Is the future focal?

Poster Session 57

  • Location:
    Room Munich, North Hall (Level 1)
  • Chairs:
     E. Barret, Paris (FR)
     B. Hollenbeck, Ann Arbor (US)
     M. Valerio, Lausanne (CH)
  • Aims and objectives of this session

    The aim of this session is to update delegates on the use of focal therapy and non-whole gland treatments.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
758
Intra-prostatic injection of PRX302 to focally ablate clinically significant prostate cancer: An open label, phase 2a study

By: Shanmugabavan Y.1, Bass E.1, Hulme A.2, Freeman A.3, Brew-Graves C.1, Potyka I.1, Ramachandran N.4, Emberton M.1, Ahmed H.U.1

Institutes: 1University College London, Division of Surgery and Interventional Sciences, London, United Kingdom, 2Sophiris, Sophiris Bio Corporation, California, United States of America, 3University College London Hospital, Dept. of Histopathology, London, United Kingdom, 4University College London Hospital, Dept. of Radiology, London, United Kingdom

759
Impact of the use of N2O for general anesthesia during high intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer

By: Potiron E.1, Lacoste J.2, Le Goguic G.2, Rousseau T.2, Nevoux P.2

Institutes: 1Clinique Urologique Nantes Atlantis, Dept. of , Saint Herblain, France, 2Clinique Urologique Nantes Atlantis, Dept. of, Saint Herblain, France

760
Prospective comparative analysis of oncologic and functional outcomes between focal therapy and robotic radical prostatectomy

By: Garcia Barreras S.1, Sanchez-Salas R.1, Sivararam A.2, Secin F.3, Redondo C.1, Velilla G.1, Barret E.1, Nunes-Silva I.1, Srougi V.1, Baghdadi M.1, Galiano M.1, Rozet F.1, Cathala N.1, Mombet A.1, Prapotnich D.1, Cathelineau X.1

Institutes: 1Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, 2Memorial Sloan Kettering, Dept. of Urology, New York, United States of America, 3CEMIC, Dept. of Urology, Buenos Aires, Argentina

761
A phase III study comparing partial prostate ablation versus radical prostatectomy (PART) in intermediate risk prostate cancer – initial data from the feasibility study

By: Leslie T.1, Elliott D.3, Le Conte S.1, Brewster S.2, Sooriakumaran P.1, Bryant R.1, Dudderidge T.4, Rosario D.5, Catto J.5, Hindley R.6, Emberton M.7, Ahmed H.7, Donovan J.3, Hamdy F.1

Institutes: 1Oxford University – Churchill Hospital, Dept. of Urology, Oxford, United Kingdom, 2Churchill Hospital, Dept. of Urology, Oxford, United Kingdom, 3University of Bristol, Dept. of Social and Community Medicine, Bristol, United Kingdom, 4University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, 5Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom, 6Basingstoke and North Hampshire Hospital, Dept. of Urology, Basingstoke, United Kingdom, 7University College London Hospital, Dept. of Urology, London, United Kingdom

762
First repeated biopsy represents the most informative predictor of progression-free survival at 3 years follow-up in patients included in an active surveillance protocol for low-risk prostate cancer

By: Luzzago S.1, Suardi N.1, Dell’Oglio P.1, Fossati N.1, Capitanio U.1, Gandaglia G.1, Zaffuto E.1, Mirone V.2, Bertini R.1, Damiano R.4, Freschi M.3, Gaboardi F.1, Montorsi F.1, Briganti A.1

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2“Federico II” University, Dept. of Urology, Naples, Italy, 3Vita-Salute University San Raffaele, Dept. of Pathology, Milan, Italy, 4Magna Graecia University, Dept. of Urology, Catanzaro, Italy

763
A nomogram for prediction of local cancer recurrence after primary prostate cryoablation

By: El Shafei A.1, Tay K.J.2, Ross A.3, Given R.4, Parsons J.K.5, Mouraviev V.6, Polascik T.2, Jones J.S.1

Institutes: 1Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, United States of America, 2Duke Cancer Institute, Dept. of Urology, Durham, United States of America, 3The Johns Hopkins Medical Institution, Dept. of Urology, Baltimore, United States of America, 4Eastern Virginia Medical School, Dept. of Urology, Virginia, United States of America, 5UC San Diego Health System, Dept. of Urology, San Diego, United States of America, 6Global Robotics Institute, Dept. of Urology, Celebration, United States of America

764
MRI-guided transurethral ultrasound ablation in patients with localized prostate cancer: 24-month outcomes of a prospective phase I clinical trial

By: Chin J.1, Relle J.2, Billia M.1, Siddiqui K.M.1, Kuru T.3, Hatiboglu G.3, Ionel V.P.3, Hafron J.2, Matthias R.3, Mueller-Wolf M.3, Zahra K.3, Kibria F.4, Burtnyk M.4, Schlemmer H-P.3, Pahernik S.3

Institutes: 1Western University, Dept. of Urology, London, Canada, 2Beaumont Health System, Department of Urology, Dept. of Urology and Radiology, Royal Oak , United States of America, 3German Cancer Research Center (DKFZ), Dept. of Urology and Radiology, Heidelberg, Germany, 4Profound Medical Inc., Dept. of Engineering, Toronto, Canada

765
Withdrawn

By:

Institutes:

766
Neoadjuvant hormonal therapy for patients with low risk prostate cancer stimulates lymphvessel invasion and shorten biochemical recurrence-free survival periods

By: Miyata Y.1, Mochizuki Y.1, Shida Y.1, Matsuo T.1, Hakariya T.1, Ohba K.1, Furusato B.2, Fukuoka J.2, Sakai H.1

Institutes: 1Nagasaki University Graduate School of Biomedical Scieneces, Dept. of Urology, Nagasaki, Japan, 2Nagasaki University Hospital, Dept. of Pathology, Nagasaki, Japan

767
Salvage prostate cryoablation in older men

By: Parsons K.2, Ross A.3, El Shafei A.1, Hatem A.1, Cotta B.2, Tay K.J.4, Polascik T.4, Given R.5, Mouraviev V.6, Jones J.S1

Institutes: 1Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, United States of America, 2UC San Diego Health System, Dept. of Urology, San Diego, California, United States of America, 3The Johns Hopkins Medical Institution, Dept. of Urology, Baltimore, United States of America, 4Duke Cancer Institute, Dept. of Urology, Durham, United States of America, 5Eastern Virginia Medical School, Dept. of Urology, Virginia, United States of America, 6Global Robotics Institute, Dept. of Urology, Celebration, United States of America

* 768
Current national trends in the management of locally advanced prostate cancer with radical therapies: Results from the English National Prostate Cancer Audit

By: Sujenthiran A.1, Nossiter J.1, Charman S.1, Aggarwal A.1, Cathcart P.2, Payne H.3, Clarke N.4, Van Der Meulen J.1

Institutes: 1Royal College of Surgeons, Clinical Effectiveness Unit, London, United Kingdom, 2Guy’s and St Thomas’ NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 3University College London Hospitals, Dept. of Oncology, London, United Kingdom, 4The Christie and Salford Royal NHS Foundation Trusts, Dept. of Urology, London, United Kingdom

V46
MRI/US fusion office-based targeted cryoablation with local anesthesia

By: Bianco F., Lozano-Kaplun S., Cedeno J., Barashi N., Scher J., Kaufman A., Lopez A., Nicholson M.

Institutes: Urological Research Network, Dept. of Urology, Miami Lakes, United States of America

Summary
 E. Barret, Paris (FR)